Neural stem cells (NSCs) persist in the subventricular zone lining the ventricles of the adult brain. The resident stem/progenitor cells can be stimulated in vivo by neurotrophic factors, hematopoietic growth factors, magnetic stimulation, and/or physical exercise. In both animals and humans, the differentiation and survival of neurons arising from the subventricular zone may also be regulated by the trophic factors. Since stem/progenitor cells present in the adult brain and the production of new neurons occurs at specific sites, there is a possibility for the treatment of incurable neurological diseases. It might be feasible to induce neurogenesis, which would be particularly efficacious in the treatment of striatal neurodegenerative conditions such as Huntington's disease, as well as cerebrovascular diseases such as ischemic stroke and cerebral palsy, conditions that are widely seen in the clinics. Understanding of the molecular control of endogenous NSC activation and progenitor cell mobilization will likely provide many new opportunities as therapeutic strategies. In this review, we focus on endogenous stem/progenitor cell activation that occurs in response to exogenous factors including neurotrophic factors, hematopoietic growth factors, magnetic stimulation, and an enriched environment. Taken together, these findings suggest the possibility that functional brain repair through induced neurorestoration from endogenous stem cells may soon be a clinical reality.
INTRODUCTION
Stem cells have two essential properties: self-renewal and multipotency. Self-renewal is the ability to generate an identical daughter cell, and multipotency is the capacity to generate many cell types (40, 130) . Because of these abilities, stem cells can continuously generate unaltered cells and also have the ability to produce many different cell types with more restricted properties. Multipotent neural stem cells (NSCs), which are capable of giving rise to both neurons and glia, persist in the subventricular zone (SVZ) lining the ventricles of the adult animal and the human brain. These cells may be mobilized and differentiated into neuronal cells in vivo by stimulating resident stem/progenitor cells with neurotrophic/growth factors via overexpression using viral vectors, chronic infusion using osmotic pumping, paracrine actions by transplanted stem cells, magnetic stimulation, and/or physical exercise.
In the adult mammalian brain, new neurons are continuously generated in the SVZ and dentate gyrus of the hippocampus. If the number of newly generated cells increases, the cells can differentiate toward a neuronal fate (12, 114, 142, 161) . The SVZ contains the largest pool of neural stem/progenitor cells, consisting of the following cell types: NSCs (type B cells), transit amplifying progenitor cells (type C cells), and migrating neuronal progenitor cells (type A cells) (5, 7, 8, 10, 49) . These cells migrate through the rostral migratory stream into the olfactory bulb, where they differentiate into new interneurons (34, 80) . The proliferation, migration, survival, and differentiation of these cells in vivo and neurons arising from the adult SVZ may be regulated by various growth factors or neurotrophic factors such as brain-derived neurotrophic factor (BDNF), epidermal growth factor (EGF), fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), stromal cellderived factor-1 (SDF-1), platelet-derived growth factor (PDGF), erythropoietin (EPO), and granulocyte colonystimulating factor (G-CSF), among others (5, (8) (9) (10) 16, 21, 77, 78, 85, 93, 102, 127, 146, 184) . Previous studies in animal models have also shown that the SVZ can respond to insults by producing new progenitor cells that can migrate to sites that have been affected by neurodegenerative diseases or brain injury (8, 9) . Progenitor cell production and migratory proteins are upregulated in the SVZ after a seizure or stroke, leading to an increase in the number of newly generated neurons, whereas there are fewer proliferating cells in the SVZ of Alzheimer's disease (AD) and Parkinson's disease (PD) patients (8, 9) .
The presence of stem/progenitor cells in the adult brain and the fact that production of new neurons occurs at specific sites suggest the possibility for a treatment of otherwise incurable neurological diseases. The set of circumstances suggests that it may be feasible to induce neurogenesis. This strategy could be particularly efficacious in striatal neurodegenerative conditions such as Huntington's disease (HD), as well as cerebrovascular diseases such as ischemic stroke and cerebral palsy, conditions that are widely seen in the clinics. More broadly, understanding of the molecular control of endogenous NSC activation and progenitor cell mobilization will likely provide many new opportunities for the use of induced neuronal replacement as a therapeutic strategy for neurodegenerative or cerebrovascular diseases (60) .
Enhanced neurogenesis has been reported in animal stroke models and even in stroke patients (75, 76, 134) , suggesting a potential avenue for the treatment of ischemic stroke. Previous studies have demonstrated that cerebral ischemia increased neurogenesis both in the hippocampus and SVZ of the adult brain (12, 75, 178) . Neuronal precursors of the SVZ migrate to the ischemic zone of the adjacent striatum and to the ischemic zone of the cerebral cortex where the damaged neurons are differentiated and replaced (12, 75, 178) . However, it is now apparent that endogenous neurogenesis is not a standalone consideration for complete functional recovery from stroke because compensatory neurogenesis induced after brain damage is largely limited (134). Therefore, in this review, we will focus on endogenous stem/progenitor cell activation that occurs in response to exogenous factors including neurotrophic factors, hematopoietic growth factors, magnetic stimulation, and an enriched environment (38, 70, 74, 137) .
NEUROTROPHIC FACTORS
Neurotrophic growth factors have an array of activities in the nervous system that consist of functions in development, plasticity, neurogenesis, disease, and injury (68). Adult neurogenesis may be enhanced by growth factors such as BDNF (16, 28, 184) , EGF (21, 93, 184) , 93, 107, 127, 157) , VEGF (22, 74, 179) , 189) , HGF (145, 188) , 100), and PDGF (34, 38) . Among multiple approaches to exogenous trophic factor delivery, experimental studies have employed injection of viral vectors (16, 22) or continuous infusion via an osmotic pump (77, 85, 93, 146, 184) (Table 1) .
Previous animal studies reported the induction of striatal regeneration from the endogenous stem/progenitor cells and functional recovery by the intraventricular administration of BDNF and EGF in hypoxic-ischemic brain injury (72) and HD (184). Infusion of EGF and FGF-2 for 2 weeks into the lateral ventricle of adult rats also increased the proliferation of neural progenitor cells (93). Chronic infusion of FGF-2 into the lateral ventricle of adult rats resulted in an increase in the population of proliferating precursors in the SVZ and a subsequent increase in the number of neurons migrating from the SVZ to the olfactory bulb (93). Likewise, administration of FGF-2 has been shown to promote neurogenesis in both the intact and ischemic brain (62,107). Using a viral delivery system of neurotrophic genes, subependymal overexpression of BDNF induced neuronal recruitment from endogenous neural progenitor cells in the SVZ of the adult mammalian forebrain (16). While BDNF induced neural progenitors to promote neuronal differentiation, the combination of BDNF and noggin potentiated neostriatal neurogenesis, by suppressing progliogenic factor bone morphogenetic protein and astroglial differentiation, expanded neural progenitor pool responsive to BDNF, and slowed disease progression in a transgenic model of HD (28).
The potential to utilize endogenous neurogenesis for the treatment of neurodegenerative diseases has been investigated (63). Neurogenesis often appears in parallel with angiogenesis (3). Indeed, NSCs were found to extend long cytoplasmic processes, with their endfeet contacting nearby striatal vessels (101). Moreover, hippocampal neurogenesis appears to occur in intimate association with angiogenesis, suggesting that VEGF might be involved in both processes (22, 77) . IGF-1 enhanced endothelial function as well as neurogenesis (62, 189) . HGF and SDF-1 also participated in angiogenesis and neurogenesis during physiological and pathological processes including brain development and brain injury such as middle cerebral artery occlusion (MCAO) (145, 188) . Additionally, treatment of stem cells derived from the fetal or adult brain with PDGF induces their differentiation into neuronal cells (78, 93) . NSCs in the SVZ can also promote angiogenesis by secreting several angiogenic factors such as VEGF, 105, 134) . Taken together, these findings indicate that neurotrophic factors play an important part in neuron-target interactions in the BDNF, brain-derived neurotrophic factor; EGF, epidermal growth factor; IGF-1, insulin growth factor-1; FGF-2, fibroblast growth factor-2; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; SDF-1, stromal cell-derived factor-1; LV, lateral ventricle; SVZ, subventricular zone; SGZ, subgranular zone; HD, Huntington's disease; MCAO, middle cerebral artery occlusion; TBI, traumatic brain injury; ICV, intracerebroventricular. adult brain. Administration of neurotrophic factors could be a potential therapeutic approach not only to prevent the progression of neurodegenerative diseases, but also to improve behavioral function following induced neurogenesis from endogenous stem/progenitor cells in neurodegenerative diseases or cerebrovascular diseases. Animal studies seem to indicate a robust response to infusion of neurotrophic factors; however, few mature neurons are actually formed, and appropriate new axonal connections with distant targets are even fewer (63). Several clinical trials have reported that neurotrophic factor treatments exhibit many drawbacks, including side effects, and some beneficial effects in neurodegenerative diseases (159). We have summarized the outcomes of clinical trials on neurotrophic factors, including nerve growth factor (NGF) (48, 118, 165) , ciliary neurotrophic factor (CNTF) (18), glial cell line-derived neurotrophic factor (GDNF) (58, 94, 116, 121) , and BDNF (15,117), for common neurodegenerative conditions (68, 159) in Table 2 . Studies on NGF infusion have shown that intraventricular administration is also associated with significant side effects, such as hypophagia and neuropathic pain, although long-term administration of NGF may offer potentially beneficial effects (48, 174) . GDNF infusion provided no significant benefits (94, 116) or modest improvement in motor function and health-related quality of life score (58,121) to human patients with PD. CNTF can be safely delivered into the brain of HD patients (18). Side effects without significant benefits of treatments were reported with intrathecal infusion of recombinant BDNF in patients with amyotrophic lateral sclerosis (ALS) (15, 117) . To a great disappointment, previous clinical trials have failed to achieve striking success (159). Nevertheless, the failure to demonstrate clinical efficacy may be due to the models used to predict the actions of a drug in the human system.
HEMATOPOIETIC GROWTH FACTORS
Hematopoietic growth factors such as EPO and G-CSF are likely to play broad roles not only in the circulatory system but also in the brain because receptors for both are expressed in the brain (12, 65, 140, 183) . In neurological diseases, exogenous administration of EPO and/or G-CSF can have effects on experimental studies (Table 3) (36,37,131,167) and clinical trials (Table 4 ). These beneficial effects have been attributed to multiple neuroprotective mechanisms including antiapoptosis, anti oxidant actions, and restoration of blood-brain barrier (BBB) integrity as well as stimulation of neurogenesis and angiogenesis (99, 150, 171, 183) . Interestingly, hematopoietic growth factors also influence the proliferation of neural precursor cells. Previous investigators reported on the individual capability of EPO or G-CSF to stimulate proliferation and differentiation of neural stem/progenitor cells in the brain (141, 146, 172) . Furthermore, a combination of G-CSF and EPO could synergistically promote proliferation of the neural progenitor cells residing in the hippocampus and SVZ (103). Exogenous hematopoietic growth factors delivered to the brain can stimulate endogenous neural stem/progenitor cells in the SVZ to promote tissue repair after injury (39, 173) .
EPO is the major growth regulator of the erythroid cell lineage. Its main biological functions are to regulate proliferation, maturation, and survival of erythroid progenitor cells in bone marrow. These functions result in an oxygendependent regulation of red blood cell mass. Additionally, endogenous stem/progenitor cell stimulation with EPO has resulted in proliferation, migration, and maturation as well as promoting regeneration and replacement of cells and tissues lost following stroke (43, 171, 173) . In contrast, infusion of EPO blockers has the opposite effect; there was a decrease in the number of newly generated cells migrating to the olfactory bulb (146). In clinical trials, EPO has demonstrated both safe and beneficial effects in acute stroke patients (44, 182) . Improvements in outcome scales and reduction in infarct size were shown to be associated with increases in cerebrospinal fluid EPO and S100b (1, 44, 177) . EPO enhances the circulating levels of endothelial progenitor cells, which have been reported to be associated with positive prognostic outcomes in ischemic stroke patients (181, 182) . However, in the randomized phase II/III German Multicenter EPO Stroke Trial, previous results from preclinical trials were not replicable in over 533 patients (45) . The failure of EPO in clinical studies may be due to an inadequate dose, since the receptors responsible for organ protection may require higher concentrations than the receptors responsible for erythropoiesis (122). Meanwhile, recent clinical trials have reported that subcutaneously administered EPO significantly improves long-term neurological outcomes in patients after acute ischemic stroke (164).
G-CSF has been widely used clinically to elicit hematopoietic stem cell mobilization into systemic circulation after life-saving bone marrow transplantation for the prevention and treatment of chemotherapy-induced neutropenia and apheresis (26, 81, 95, 120, 162, 183) . Systemically given G-CSF was able to pass the intact BBB. This property is shared with other hematopoietic factors, such as EPO (19) and granulocyte macrophage colonystimulating factor (GM-CSF) (109), showing neuroprotective activities in models of focal cerebral ischemia (141). G-CSF has been shown to promote structural and functional regeneration of the central nervous system (CNS) in stroke patients. It can also act as a neurotrophic factor, induce neurogenesis, and counteract apoptosis. These properties suggest a major role for its use in the development of treatments of neurological diseases, such as cerebral ischemia (2,123,141). G-CSF activates intracellular signaling pathways including STAT3 (27) and Akt (42), which are both linked to suppression of apoptosis and proliferation (141). G-CSF-induced STAT activation might operate an autocrine VEGF loop in NSCs and subsequently enhance neurogenesis (79). In clinical trials, G-CSF treatment has demonstrated safety and improvement in neurological outcomes and reduction of infarct size in acute and subacute stroke (4, 138, 147, 153) .
Recent studies have shown that G-CSF treatment in both subacute and elderly chronic stroke patients is safe and reasonably well tolerated (2, 46, 54) . Of note, G-CSF treatment facilitated CD34 + hematopoietic stem cell mobilization and increases in leukocyte counts (51). G-CSF also improved functional results by facilitating the recruitment of CD34 + cells to the infarct area, mobilizing them through the BBB, and promoting the generation of neurotrophic factors and VEGF (51). However, other studies reportedly failed to find effects of G-CSF in improving neurological outcomes in patients with acute and subacute stroke (126, 129) . Despite contrary results, G-CSF might exert its clinical effects by promoting the mobilization of blood CD34 + stem cells in stroke patients.
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Transcranial magnetic stimulation was introduced in 1985 as a neurological technique for noninvasively inducing motor movement by direct magnetic stimulation of the brain's motor cortex to measure connectivity and excitability (14, 33, 64, 82, 133) . This procedure depends on the basic principle of mutual induction, whereby magnetic fields can be converted into electrical energy. If the electrical field falls in a conductor, the electrical current will consequently flow into the brain tissue. The nature of repetitive transcranial magnetic stimulation (rTMS) means that the stimulus can be repeated for a few seconds at frequencies up to 50 Hz (55, 128, 169) .
rTMS is a noninvasive therapeutic device that can alter the excitability of the cerebral cortex or neural network. Many studies have reported that rTMS treatment has therapeutic benefits in both experimental studies (Table 5) and clinical trials (Table 6 ). There is evidence that rTMS causes changes in neuronal circuits as reflected by behavioral changes (55, 108, 125) . Possible mechanisms include the release of neurotransmitters, synaptic efficiency, and alteration of signaling pathways and gene expression (66, 73, 125) . Recent studies have reported that long-term rTMS treatment significantly elevated BDNF in the hippocampus, parietal cortex, and piriform cortex (113). The rTMS also modulated various neurotrophic factors such as BDNF, GDNF, NGF, PDGF, VEGF, cholecystokinin, and neuropeptide tyrosine in ALS (6), depression (57,186), and PD (96). Effects on neurotrophic factors could possibly explain preliminary findings of neuroprotective and neurotrophic effects of rTMS on degenerated dopaminergic neurons of the substantia nigra in 6-OHDA-induced PD rats and mossy fiber sprouting in the hippocampus following chronic rTMS (96).
Additionally, previous studies have suggested that long-term rTMS treatment induced in situ differentiation of SVZ-derived precursors into dopamine-producing neurons in a PD rat model with unilateral 6-OHDA-lesioned substantia nigra, and reduced amphetamine-induced rotations in behavioral experiments (11). Long-term rTMS treatment was also related to an increase in cell proliferation in the hippocampus. The treatment modulated the signaling pathway of ERK and increased BDNF protein expression in the hippocampus in mice with depression (52,166). However, the effect of rTMS on neurogenesis has not been well studied in stroke models.
Depending on its frequency and intensity, rTMS can temporarily enhance or inhibit excitability, and it can produce consistent and long-lasting effects on physiology within the cortex (124) and deep brain sites connected to the cortex (112). Previous studies showed that the neurogenic effects of rTMS can vary according to frequency and intensity (106, 135) . Investigations showed that cultured hippocampal neurons treated at a low frequency (1 Hz) had an increased number of processes and neurite length as well as altered ultrastructural parameters of the synapses, while high-intensity stimulation disrupted synaptic structure and was accompanied by a decreased survival rate and increased rate of apoptosis. However, the mechanisms of rTMS-mediated effects on neurogenesis in vivo still remain to be elucidated.
In clinical studies, rTMS has been used to treat neuropsychiatric diseases (17, 53, 190) and stroke (30, 158) . Several clinical trials have also revealed that rTMS offers therapeutic benefits on functional recovery after PD (7, 148, 176, 180) . rTMS treatment has been shown to improve motor function and cognition in patients with PD (187). Additionally, increased dopamine levels in serum and subcortical areas have been observed following rTMS in PD patients and experimental animals (23, 29, 86, 155) . Nevertheless, the underlying mechanism of rTMS still remains to be elucidated. Recently, several experiments have shown that rTMS has the ability to mediate neuroplasticity by enhancing the expressions of glutamate neurotransmitters and BDNF in rat brains (83, 113, 185) . rTMS not only activated brain regions in terms of immediate early gene expression but also increased the expression of BDNF-TrkB signaling in rats and humans (41, 66, 73, 170) . Additionally, rTMS was found to modulate neurotrophic factors such as BDNF, cholecystokinin, and neuropeptide tyrosine, in healthy humans and patients with depression and ALS (6, 186) . A previous study suggested that rTMS may promote neurogenesis in the medial temporal lobe or have other effects that favor neuronal plasticity and may also be neuroprotective for patients with treatmentresistant major depressive disorders (56), whereas another study reported that serial high-frequency rTMS over the left dorsolateral prefrontal cortex decreased serum BDNF levels in healthy male volunteers (139).
PHYSICAL EXERCISE AND ENRICHED ENVIRONMENT
Rearing animals in an enriched environment is a classic paradigm that has been used extensively in juvenile and adult rodents to study the effects of a complex combination of physical, cognitive, and social stimulation (98, 132 ). An enriched environment can facilitate biochemical and morphological changes in the adult brain and promote functions in animals with brain injuries (98, 175) . Many studies have shown that environmental stimulation elicits various plastic responses in the adult brain, ranging from biochemical parameters to dendritic arborization, gliogenesis, and neurogenesis (32, 71, 98) . Additionally, an enriched environment induces pronounced enhancement of neuronal elements such as neuronal cell body and nucleus size, dendritic branching, dendritic spine density, and the number of synapses (87, 151, 152, 168) .
Physical exercise and an enriched environment have a differential influence on neural stem/progenitor cells in the experimental studies (Table 7) . Whereas physical exercise was found to increase the generation of early and late neural progenitors as well as increase gliogenesis, an enriched environment increased the neuronal differentiation of progenitor cells (87, 92, 154) . The neurogenic effect of physical exercise manifests itself in the early stage of neuronal development through increased cell proliferation (92). On the other hand, the effect of an enriched environment on hippocampal cell genesis has been shown to include specific neurogenesis-promoting effects without having any influence on the generation of astrocytes (84, 87 ). An environmental enrichment also has a survival-promoting effect on the progeny of neuronal precursor cells in the hippocampus. These neurons added to an increased granule cell number and hippocampal volume in an animal model (84). According to another study, the number of newborn cells in the dentate gyrus of the hippocampus was not altered 1 day after bromodeoxyuridine (BrdU) injections, whereas the number of surviving progenitors 1 month after BrdU injections was markedly increased in animals housed in an enriched environment. The increased number of progenitor progeny is most likely a result of increased survival of newborn progenitor progeny rather than an increase in the number of mitotic divisions among progenitor cells (115).
While the enriched housing and voluntary running exercise enhanced migration and survival of transplanted stem cells toward the injured region after stroke, postischemic exercise and an enriched environment differentially modulated SVZ cell genesis. An enriched environment increased the number of endogenous progenitor cells in the SVZ, suggesting that functional recovery can be augmented by environmental factors such as rehabilitation (69). On the other hand, wheel-running exercise after cortical infarction was found to attenuate the early poststroke activation of the SVZ germinal niche (87, 90) . In contrast to postischemic exercise, an enriched environment did not have attenuating effects on the SVZ activation, but increased proliferating NSCs and neuronal precursors (90). Additionally, treadmill exercise suppressed ischemiainduced apoptosis in the hippocampal dentate gyrus following transient global ischemia in gerbils, suggesting the possibility that treadmill exercise aids in recovery from stroke (87, 97) . Adult hippocampal neurogenesis is a dynamic process that can be influenced by physiological and pathological factors. Postischemic-enriched housing did not significantly influence the total rate of mitotic cells or newborn neurons in the hippocampus. However, an enriched environment after cortical infarction enhanced hippocampal gliogenesis (87,88), increasing the ipsilateral generation of astrocytes normalizing the astrocyte-to-neuron ratio, which was significantly reduced in rats housed in standard cages (88). The findings of increased astrogliogenesis in the germinal niches in addition to increased generation of NG2 + glia and newborn surviving reactive astroglia in the postischemic neocortex suggest that some of the beneficial effects of an enriched environment on the postischemic brain might be mediated through a dynamic modulation of glial populations (89). Other studies reported no effects of physical exercise (20) or an enriched environment (20,87,89) on hippocampal progenitor cell proliferation after transient global ischemia in rats, although possible accelerated neuronal maturation was observed in enriched animals (20, 87, 89) .
Physical exercise or an enriched environment as a rehabilitation therapy could play a role in therapies, either by itself alone or adjuvant to drug treatments or cell transplantation (63,143). As a mechanism for endogenous brain repair, rehabilitation exercise training induced neuronal differentiation in the dentate gyrus of the hippocampus (20, 84, 87) . Particularly, enhanced maturation of newly formed cells was seen only with an enriched environment, raising the possibility that behavioral experience in a complex environment may be used as a rehabilitation strategy following ischemic insult (20) . The lack of additional effects of physical exercise or an enriched environment on stroke-induced hippocampal neurogenesis suggests common pathways of regulation by lesion and by environmental interventions. Several studies have shown that, in a brain lesion, VEGF, IGF-1, or FGF-2 mediate the neurogenesis-promoting effects of an enriched environment and physical exercise (50, 87, 143, 144, 163) . This possible mechanism was validated by inhibiting VEGF expression by RNA interference, which completely blocked the environmental induction of neurogenesis (22) . The activation of BDNF and IGF-1 is related to neuroplasticity and can be measured both indirectly via serum in humans and directly from tissue in animals. The activation of these pathways improves trophic communication between neurons, thereby improving neuroplasticity. These molecular pathway activators culminate in neuroplasticity, as well as decrease apoptosis and oxidative stress (24, 149) .
Recent clinical trials have reported that patients with schizophrenia can benefit from resistance training; the program improved the mechanical efficiency of walking (67, 149) . Aerobic training also increases hippocampal volume in schizophrenia (119, 149) . However, no changes in BDNF or IGF-1 were observed in the study groups. In line with these results, recent studies have found no changes in BDNF or IGF-1 in patients with major depression exposed to a 3-month aerobic exercise intervention (91, 149) . Whereas other studies have also shown that resistance training does not increase serum concentrations of BDNF (59,156), it increases IGF-1 (25). On the other hand, aerobic training has been found to increase serum BDNF (13,61).
Although the biological mechanism of physical exercise is not clear, many clinical studies indeed show that exercise improves physical fitness in stroke patients (Table 8) . For this reason, fitness training has been proposed as a beneficial approach for stroke patients. Some types of fitness trainings, particularly those involving walking, can improve exercise ability, walking, and balance after stroke (136). In stroke patients who have difficulties with walking, electromechanical-assisted gait training, using specialized machines to assist in walking, may improve recovery of independent walking in people after stroke (110). Another study investigating the effectiveness and safety of circuit class therapy on mobility in patients with stroke also reported the benefits of circuit classes in improving mobility (47). Additionally, treadmill training reportedly improved gait parameters in patients with PD (111). Thus, physiotherapy can be applied to maximize functional ability and minimize secondary complications through movement rehabilitation. While clinical trials have shown that physiotherapy has short-term benefits in PD, it is still unclear which approach is most effective (160). Meanwhile, the effects of exercise in ALS patients are not well understood. When weak muscles are worked beyond their maximal limits, they can be damaged (35). In addition, there is not enough information to draw reliable conclusions concerning the impact of fitness training on quality of life in stroke patients (136) . Therefore, further research should address what frequency, duration, or period of exercise might be most effective at any stage or severity, if some tasks are better to practice than others (110), and underlying mechanisms such as induction of neurorestoration from endogenous neural stem cells. participants Cardiorespiratory training reduces disability after stroke, and this may be mediated by improved mobility and balance. There is sufficient evidence to incorporate cardiorespiratory and mixed training, involving walking, within poststroke rehabilitation programs to improve the speed and tolerance of walking; improvement in balance may also occur Saunders et al. (136) Automated electromechanical and robotic-assisted gait training Stroke 23 trials, involving 999 participants People who receive electromechanical-assisted gait training in combination with physiotherapy after stroke are more likely to achieve independent walking than people who receive gait training without these devices. Specifically, people in the first 3 months after stroke and those who are not able to walk seem to benefit most from this type of intervention. Mehrholz et al. (110) Circuit class therapy Stroke Six trials, involving 292 participants CCT is safe and effective in improving mobility for people after moderate stroke and may reduce inpatient length of stay English and Hillier (47) Treadmill training PD 18 trials, involving 633 participants Treadmill training did improve gait speed, and stride length, but walking distance and cadence did not improve. It seems that such devices could be beneficial and could be applied in routine rehabilitation Mehrholz et al. (111) Various physiotherapy interventions (general physiotherapy, exercise, treadmill training, cueing, dance, or martial arts) PD 43 trials, involving 1,673 participants A wide range of different physiotherapy techniques have been tested to treat PD. Considering the small number of participants, the wide variety of physiotherapy interventions and the outcomes assessed, there is insufficient evidence to support the use of one approach of physiotherapy intervention over another for the treatment of PD Tomlinson et al. (160) Exercise program ALS Two trials, involving 43 participants Only two randomized studies of exercise in people with ALS. The trials compared an exercise program with usual care (stretching exercises). Combining the results from the two trials, exercise produced a greater average improvement in function (measured using an ALS-specific measurement scale) than usual care Dal Bello-Haas and Florence (35) ALS, amyotrophic lateral sclerosis; PD, Parkinson's disease; CCT, circuit class therapy.
CONCLUSION
That stem/progenitor cells are present in the adult brain and that the production of new neurons occurs in specific sites of the SVZ and hippocampus suggests the possibility of a treatment for neurological diseases. We reviewed neurorestoration from endogenous stem cells by exogenous factors including neurotrophic factors, hematopoietic growth factors, magnetic stimulation, and an enriched environment in both experimental studies and clinical trials. Taken together, these findings suggest the possibility that functional brain repair through induced neurorestoration from endogenous neural stem cells may soon be a clinical reality. ACKNOWLEDGMENTS: This study was supported by grants from the National Research Foundation (NRF-2014R1A2 A1A11052042, NRF-2015M3A9B4067068), the Ministry of Science and Technology, Republic of Korea. The authors declare no conflicts of interest.
